Document
IPR2018-01714, No. 1040-40 Exhibit - Weber, D, et al, Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America, N Engl J Med 357212133 2142 2007 (P.T.A.B. Sep. 12...
Cite Document
IPR2018-01714, No. 1040-40 Exhibit - Weber, D, et al, Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America, N Engl J Med 357212133 2142 2007 (P.T.A.B. Sep. 12, 2018)
+ More Snippets
Document
IPR2018-01714, No. 1055-55 Exhibit - Declaration of James L Mullins, PhD Part 1 of 5 (P.T.A.B. Sep. 12, 2018)
Cite Document
IPR2018-01714, No. 1055-55 Exhibit - Declaration of James L Mullins, PhD Part 1 of 5 (P.T.A.B. Sep. 12, 2018)
+ More Snippets
Document
IPR2018-01714, No. 1005 Exhibit - Tramontana et al, Thalidomide Treatment Reduces Tumor Necrosis Factor ¿¿ Production and Enhances Weight Gain in Patients with Pulmonary Tuberculosis, M...
Cite Document
IPR2018-01714, No. 1005 Exhibit - Tramontana et al, Thalidomide Treatment Reduces Tumor Necrosis Factor ¿¿ Production and Enhances Weight Gain in Patients with Pulmonary Tuberculosis, Molecular Medici
+ More Snippets
Document
IPR2018-01714, No. 1029 Exhibit - Parameswaran et al, CCNU lomustine, idarubicin and dexamethasone CIDEX an effective oral regimen for the treatment of refractory or relapsed myeloma, Br...
Cite Document
IPR2018-01714, No. 1029 Exhibit - Parameswaran et al, CCNU lomustine, idarubicin and dexamethasone CIDEX an effective oral regimen for the treatment of refractory or relapsed myeloma, Br J Haematol, 1
+ More Snippets
Document
IPR2018-01714, No. 1039 Exhibit - Gay, F, et al, Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma a comparative analysis of 411...
Cite Document
IPR2018-01714, No. 1039 Exhibit - Gay, F, et al, Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma a comparative analysis of 411 patients, Blood
+ More Snippets
Document
IPR2018-01714, No. 1027 Exhibit - Pomalyst Label (P.T.A.B. Sep. 12, 2018)
Cite Document
IPR2018-01714, No. 1027 Exhibit - Pomalyst Label (P.T.A.B. Sep. 12, 2018)
+ More Snippets
Document
IPR2018-01714, No. 1041 Exhibit - Armoiry, X, et al, Lenalidomide in the treatment of multiple myeloma a review, J Clin Pharm Ther 33219 226 2008 (P.T.A.B. Sep. 12, 2018)
Cite Document
IPR2018-01714, No. 1041 Exhibit - Armoiry, X, et al, Lenalidomide in the treatment of multiple myeloma a review, J Clin Pharm Ther 33219 226 2008 (P.T.A.B. Sep. 12, 2018)
+ More Snippets
Document
IPR2018-01714, No. 1052 Exhibit - US Provisional Application No 60380,842 (P.T.A.B. Sep. 12, 2018)
Cite Document
IPR2018-01714, No. 1052 Exhibit - US Provisional Application No 60380,842 (P.T.A.B. Sep. 12, 2018)
+ More Snippets
Document
IPR2018-01714, No. 1035 Exhibit - J Blade and J Esteve, Treatment Approaches for Relapsing and Refractory Multiple Myeloma, Acta Oncologica, 397843 847 2000 (P.T.A.B. Sep. 12, 2018)
Cite Document
IPR2018-01714, No. 1035 Exhibit - J Blade and J Esteve, Treatment Approaches for Relapsing and Refractory Multiple Myeloma, Acta Oncologica, 397843 847 2000 (P.T.A.B. Sep. 12, 2018)
+ More Snippets
Document
REVLIMID, 021880, Letter (Orange Book Aug. 31, 2021)
Cite Document
REVLIMID, 021880, Letter (Orange Book Aug. 31, 2021)
+ More Snippets
Document
REVLIMID, 021880, Letter (Orange Book Aug. 31, 2021)
Cite Document
REVLIMID, 021880, Letter (Orange Book Aug. 31, 2021)
+ More Snippets
Document
REVLIMID, 021880, Label (Orange Book Aug. 31, 2021)
Cite Document
REVLIMID, 021880, Label (Orange Book Aug. 31, 2021)
+ More Snippets
Document
REVLIMID, 021880, Letter (Orange Book Aug. 5, 2021)
Cite Document
REVLIMID, 021880, Letter (Orange Book Aug. 5, 2021)
+ More Snippets
Document
REVLIMID, 021880, Letter (Orange Book Sep. 24, 2020)
Cite Document
REVLIMID, 021880, Letter (Orange Book Sep. 24, 2020)
+ More Snippets
Document
REVLIMID, 021880, Letter (Orange Book Oct. 30, 2019)
Cite Document
REVLIMID, 021880, Letter (Orange Book Oct. 30, 2019)
+ More Snippets